Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient

In conclusion, our case suggests that daratumumab is an effective and well-tolerated alternative to chemotherapy in the treatment af AL amyloidosis in very elderly patients.PMID:35934598 | DOI:10.1016/j.revmed.2022.07.013

Source: Revue de Medecine Interne - August 7, 2022 Category: Internal Medicine Authors: G Vial A Lafargue P Merci é P Duffau E Ribeiro Source Type: research